Shares of a cancer vaccine developer soared 150% in a single day. What do analysts recommend?

Sellas Life Sciences shares soared following positive trial results for its cancer vaccine / Photo: Nan Tun Nay / Shutterstock
Shares of Sellas Life Sciences, a small biotech startup, soared 156% in a single day of trading on November 17. The company reported that its cancer vaccine reduced patients’ risk of death and helped them live longer than the best treatment currently available. Wall Street believes the company’s stock could nearly double in price.
Details
Sellas Life Sciences shares surged 156% on the Nasdaq on November 17. This marks the biggest one-day gain since 2020, according to Bloomberg. At the close, the stock reached $19.15—its highest level since 2019.
Sellas’ stock rally began after the company released interim results from the third and final phase of clinical trials for an anti-cancer vaccine called GPS (Galinpepimut-S). The vaccine was tested on patients with acute myeloid leukemia (AML), an aggressive form of blood cancer, who had achieved remission after at least two rounds of treatment but were unable to undergo a stem cell transplant.
The study showed that the GPS vaccine reduced the risk of death among people with AML by 41%. At the same time, the median survival (the point at which at least half of the patients who began treatment are still alive) for those who underwent immunotherapy was 24 months, compared with 14.7 months for the best treatment currently available.
Sellas plans to discuss with the U.S. Food and Drug Administration (FDA) the possibility of filing an application for accelerated approval of the vaccine in the first half of 2027.
After the market closed on November 17, the biotech company announced a $150 million stock offering, plus an underwriters’ option for up to $22.5 million. This led to a drop in the stock price during after-hours trading on November 17. In premarket trading on November 18, the stock price is also down 6%.
What Analysts Are Saying
“These results can be considered groundbreaking for a disease that is extremely difficult to treat. If GPS is approved, it could become the standard of care,” wrote James Molloy, an analyst at Alliance Global Partners, whose opinion is cited by Bloomberg. The agency notes that the results obtained by Sellas add to the growing body of evidence regarding the potential of cancer vaccines, following promising data on a melanoma vaccine from pharmaceutical giants Moderna and Merck & Co.
However, not all investors were betting on GPS's success, Bloomberg notes. It cites data from the analytics firm S3 Partners, according to which short positions reached 29% of Sellas’ total free-float shares, indicating bearish bets against the biotech company.
Sellas has a total of two recommendations from Wall Street analysts, both of which are “buy.” The average price target is $37.5, which implies upside potential of nearly 96% from current levels.




